{"url_path":"/sec/ktta/10-q/2026/item-1a","section_key":"item-1a","section_title":"Item 1A Risk Factors","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","accession_number":"0001213900-26-057837","cik":"0001841330","ticker":"KTTA","issuer_name":"Pasithea Therapeutics Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841330/0001213900-26-057837-index.html","primary_entity_key":"0001841330","primary_entity_name":"Pasithea Therapeutics Corp."},"word_count":195,"has_tables":true,"body_markdown":"Item 1A. Risk Factors\n\n \n\nThere have been no material changes to the risk\nfactors set forth in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December\n31, 2025, as filed on March 30, 2026. Our business involves significant risks. You should carefully consider the risks and uncertainties\ndescribed in our Form 10-K, together with all of the other information in this Quarterly Report on Form 10-Q, as well as our audited consolidated\nfinancial statements and related notes as disclosed in our Form 10-K. The risks and uncertainties described in our Form 10-K are not the\nonly ones we face. Additional risk and uncertainties that we are unaware of or that we deem immaterial may also become important factors\nthat adversely affect our business. The realization of any of these risks and uncertainties could have a material adverse effect on our\nreputation, business, financial condition, results of operations, growth and future prospects as well as our ability to accomplish our\nstrategic objectives. In that event, the market price of our common stock and Public Warrants could decline, and you could lose part or\nall of your investment."}